Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Bazedoxifene / conjugated oestrogen

Brand: Duavive ®
NICE TA: 
Indication: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

Conjugated oestrogens and bazedoxifene tablets are not recommended for prescribing for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin containing therapy is not appropriate. There is a lack of evidence demonstrating increased efficacy to mitigate the increased cost of the product.There are concerns about the adverse event profile of the product which introduces those of a new drug in addition to those already present due to the presence of oestrogen in the product.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

Bazedoxefine New Medicine Recommendation (528.1 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black

Black